Biogen CEO Says $56,000 Annual Price For Alzheimer's Drug Reflects 'Two Decades Of No Innovation'
Biogen Inc (NASDAQ: BIIB) CEO Michel Vounatsos has justified the annual $56,000 list price for its newly approved Alzheimer’s disease drug aducanumab as “fair,” CNBC
